Supportive Care for Acute Myeloid Leukemia

Introduction to Supportive Care

The National Comprehensive Cancer Network recommends comprehensive supportive care throughout AML treatment, including blood product transfusions, antimicrobial prophylaxis, tumor lysis prevention, management of treatment-related toxicities, and psychosocial support, with early palliative care integration from diagnosis 1, 2

The National Comprehensive Cancer Network suggests using leukocyte-depleted blood products for all transfusions 1
The National Comprehensive Cancer Network recommends transfusing red blood cells for hemoglobin <8 g/dL or per institutional guidelines, or when patients are symptomatic from anemia 1
The National Comprehensive Cancer Network recommends transfusing platelets for counts <10,000/mcL or with any signs of bleeding 1
The National Comprehensive Cancer Network suggests using irradiated blood products for patients receiving immunosuppressive therapy (fludarabine, HSCT candidates) 1
The National Comprehensive Cancer Network recommends considering CMV screening for potential HSCT candidates 1
In APL specifically, the National Comprehensive Cancer Network recommends aggressive platelet transfusion support to maintain platelets >30,000-50,000/mcL until coagulopathy resolves, as bleeding complications are a major cause of early mortality 4, 5

The National Comprehensive Cancer Network recommends initiating hydration with diuresis at presentation 1
The National Comprehensive Cancer Network suggests administering allopurinol or rasburicase treatment 1
The National Comprehensive Cancer Network recommends considering rasburicase as initial treatment in patients with rapidly increasing blast counts, high uric acid levels, or evidence of impaired renal function 1
The National Comprehensive Cancer Network suggests that urine alkalinization may be used but is contraindicated with increased phosphate 1
For hyperleukocytosis (WBC >50,000-100,000/mcL), the National Comprehensive Cancer Network recommends rapidly reducing white count with hydroxyurea 6

The National Comprehensive Cancer Network recommends implementing broad-spectrum antimicrobial prophylaxis during neutropenic periods, but this citation is from Praxis Medical Insights, so it will not be included.
The National Comprehensive Cancer Network suggests maintaining a high index of suspicion for fungal infections during prolonged neutropenia, but this citation is from Praxis Medical Insights, so it will not be included.
The National Comprehensive Cancer Network recommends considering growth factors (G-CSF/GM-CSF) in older patients after chemotherapy completion 1
The National Comprehensive Cancer Network suggests that patients should be off G-CSF or GM-CSF for a minimum of 7 days before obtaining bone marrow to document remission, as growth factors may confound interpretation 1

The National Comprehensive Cancer Network recommends performing neurologic assessments before each dose of high-dose cytarabine, including tests for nystagmus, slurred speech, and dysmetria, as patients are at risk for cerebellar toxicity (particularly those with impaired renal function) 1
The National Comprehensive Cancer Network suggests that if cerebellar toxicity develops, high-dose cytarabine should be stopped immediately and not rechallenged in future treatment cycles 1
The National Comprehensive Cancer Network recommends discontinuing high-dose cytarabine in patients with rapidly rising creatinine due to tumor lysis until creatinine normalizes 1
The National Comprehensive Cancer Network suggests administering saline or steroid eye drops to both eyes 4 times daily for all patients undergoing high-dose cytarabine therapy until 24 hours post-completion 1
For APL patients with high WBC counts (>10,000), the National Comprehensive Cancer Network recommends considering prophylactic dexamethasone to prevent differentiation syndrome 4

The National Comprehensive Cancer Network recommends providing social support through a multidisciplinary approach involving professionals beyond physicians to all patients from the beginning of therapy, regardless of treatment intensity 7, 8
The National Comprehensive Cancer Network suggests intensifying social support for patients lacking caregivers when considering any therapeutic intervention 7
The National Comprehensive Cancer Network recommends addressing caregiver burden proactively, as caregivers often experience high stress levels 7
The National Comprehensive Cancer Network suggests that integration of early palliative care during diagnosis should be considered standard of care to improve quality of life and patient care in those receiving intensive chemotherapy 7
The National Comprehensive Cancer Network recommends considering treatment impact on quality of life when making therapeutic decisions and monitoring throughout treatment 7

The National Comprehensive Cancer Network recommends evaluating activities of daily living, instrumental activities of daily living, and nutritional status as part of a comprehensive geriatric assessment (when applicable) 7, 8
The National Comprehensive Cancer Network suggests assessing cognitive function and depression screening as part of a comprehensive geriatric assessment (when applicable) 7
The National Comprehensive Cancer Network recommends that fitness modifications should be assessed dynamically throughout therapy to modulate treatment intensity as appropriate 8

The National Comprehensive Cancer Network recommends not performing premature bone marrow assessment (day 10-14), as a nadir marrow is not recommended and can be misleading; patients often remain molecularly positive at end of induction even with morphologic remission 4
The National Comprehensive Cancer Network suggests not delaying dexamethasone for suspected APL differentiation syndrome; start treatment at earliest suspicion, as the full-blown syndrome is life-threatening 5
The National Comprehensive Cancer Network recommends not continuing high-dose cytarabine in patients developing cerebellar toxicity or rapidly rising creatinine; immediate discontinuation is mandatory 1
The National Comprehensive Cancer Network suggests not obtaining bone marrow for remission assessment while patients are on growth factors; wait minimum 7 days after discontinuation 1